Core Insights - The stock market has seen significant declines among several companies, particularly Venus Concept Inc., IO Biotech, Inc., and Innovation Beverage Group Limited, with notable shifts in their stock values [1] Company Summaries Venus Concept Inc. (VERO) - The company experienced a 56.4% drop in stock price to $1.94, down from a year high of $14.5 to a low of $1.39 [2] - Challenges affecting investor confidence include the decision to voluntarily delist from the Nasdaq Capital Market and deregister with the SEC [2] IO Biotech, Inc. (IOBT) - IO Biotech's stock price decreased by 55.39% to $0.23, falling from a year high of $2.79 to a low of $0.20 [3] - The company focuses on immune-modulating cancer therapies and is exploring strategic alternatives, including a merger or potential liquidation, to enhance stockholder value [3] Innovation Beverage Group Limited (IBG) - The stock price of Innovation Beverage Group fell by 36.67% to $0.98, down from a year high of $9.85 to a low of $0.85 [4] - The company is pursuing energy expansion efforts and a proposed merger with BlockFuel Energy, aiming to advance its integrated energy and infrastructure strategy [4] Market Overview - The significant price movements of these companies highlight the volatile nature of the stock market and the various factors influencing investor sentiment and company valuations [5]

Core Viewpoint - Venus Concept Inc. has announced its decision to voluntarily delist from Nasdaq and cease SEC reporting due to compliance costs outweighing the benefits of remaining publicly listed [1][3]. Group 1: Delisting and SEC Reporting - The company plans to file a Form 25 with the SEC around January 30, 2026, with the last trading day on Nasdaq expected to be around February 6, 2026 [2]. - Following the delisting, Venus Concept will file a Form 15 on or about February 9, 2026, which will suspend its obligation to submit periodic SEC reports [2]. Group 2: Financial Position - As of September 30, 2025, the company's inventories were reported at $15.768 million, while cash and equivalents stood at $4.312 million [1]. Group 3: Company Overview - Venus Concept specializes in medical aesthetic technology, offering minimally invasive and non-invasive devices across more than 60 countries, including products like Venus NOVA, Venus Versa, and the ARTAS iX robotic hair restoration system [4]. - The company's stock price fell by 54.83% to $2.00, nearing its 52-week low of $1.39 [4].

Core Viewpoint - Venus Concept Inc. has announced its decision to voluntarily delist its common stock from the NASDAQ Capital Market and deregister its common stock with the SEC, citing that the costs of compliance outweigh the benefits for the company and its shareholders [1][2]. Delisting and Deregistration - The company is compliant with Nasdaq listing requirements but has determined that the resources needed for SEC reporting obligations are excessive compared to the benefits [2]. - Venus Concept has notified Nasdaq of its intent to delist and deregister, planning to file a Form 25 on or about January 30, 2026, with the last trading day expected to be around February 6, 2026 [3]. - A Form 15 will be filed on or about February 9, 2026, which will suspend the company's obligation to file periodic reports with the SEC [3]. Management's Perspective - The Board of Directors believes that this decision is in the best interests of the company and its shareholders, as it will reduce compliance costs and support the execution of the company's turnaround plan [4]. - The CEO of Venus Concept emphasized the collaboration with Madryn Asset Management to position the company for long-term financial success [4]. Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products, reaching over 60 countries [5]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare industry investors [5].

Core Insights - Venus Concept (VERO) shares surged nearly 460% on January 16 after Madryn Asset Management revealed a 91% ownership stake in the company [1] - Following the initial surge, VERO shares reversed gains, trading at approximately $4.20 compared to a high of around $13 [2] - The lack of fundamental operational improvements raises concerns about whether the price rally is based on genuine value or speculative momentum [3] Group 1 - The announcement of Madryn's ownership stake coincided with discussions on cost reduction strategies, including potential delisting and deregistration of the stock [1] - The extraordinary gains in VERO shares have led to immediate weakness, indicating unfavorable risk-reward dynamics for investors considering chasing the rally [4] - Historical data shows that Venus has averaged a decline of over 4% in February over the past eight years, making the stock less attractive in the near term [6] Group 2 - The absence of Wall Street coverage for Venus Concept is a significant concern, as it leaves investors without professional guidance on valuation and future prospects [7] - The potential for delisting signals a reduction in market accessibility and liquidity, further complicating the investment landscape for VERO shares [5] - Historical patterns suggest that chasing such significant rallies often results in suboptimal risk-adjusted returns, as profit-taking can lead to substantial retracement [5]

As of Jan. 20, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to ...

Core Insights - Three stocks in the health care sector are signaling potential warnings for momentum-focused investors as of January 20, 2026 [1] Group 1: Overbought Stocks - Venus Concept Inc (NASDAQ:VERO) has an RSI value of 95.9, with shares gaining 451.8% to close at $7.89 on Friday, and a 52-week high of $14.50 [2][5] - ImmunityBio Inc (NASDAQ:IBRX) has an RSI value of 95.4, with shares rising 39.8% to close at $5.52 on Friday, and a year-to-date increase of over 100% [2][5]

Core Viewpoint - Venus Concept Inc. (NASDAQ:VERO) experienced a significant stock price increase of over 500% on Friday, driven by high trading volume and strategic investment developments [1]. Group 1: Stock Performance - Venus Concept stock surged 593.01% to $9.91 at publication, with a trading volume of 223.09 million shares compared to an average volume of 1.74 million [1][6]. Group 2: Major Stake Acquisition - Madryn Asset Management disclosed a 91% stake in Venus Concept, indicating the investment is for strategic purposes [2]. - As a major shareholder, Madryn Asset Management plans to engage actively in operational, financial, and strategic initiatives, including evaluating potential strategic alternatives for the company [3]. Group 3: Financial Performance - Venus Concept reported third-quarter sales of $13.78 million, which fell short of the consensus estimate of $14.48 million, marking an 8% year-over-year decline and a 12% quarter-over-quarter decline, primarily due to a downturn in the Hair Restoration business [4]. Group 4: Product Development - The U.S. FDA granted 510(k) clearance to Venus Concept's Venus NOVA, a next-generation multi-application platform aimed at enhancing non-invasive treatments for various aesthetic applications [5]. - Venus NOVA features Adaptive Electrical Muscle Stimulation (EMS), Multi-Polar Radio Frequency (RF), Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse technology, providing a comprehensive solution for body contouring and skin treatments [6].

Core Insights - PainReform Ltd. announced a name change and is expanding into diversified healthcare and AI-driven energy platforms, resulting in a 27.4% increase in share price to $1.02 in pre-market trading [1] Gainers - Acco Group Holdings Limited saw a significant gain of 219.4%, reaching $9.40 in pre-market trading [4] - Venus Concept Inc. increased by 72.2% to $2.48 [4] - Jaguar Health, Inc. rose 41.3% to $1.08 following a licensing agreement with Woodward Specialty [4] - ImmunityBio, Inc. gained 22.8% to $4.85, with preliminary net product revenue for Anktiva projected at approximately $113 million for fiscal 2025, marking a 700% year-over-year increase [4] - OneMedNet Corporation rose 14.2% to $0.9711 after a previous decline [4] - Brand Engagement Network, Inc. increased by 13.8% to $6.50 [4] - Springview Holdings Ltd rose 13.4% to $19.75 after a substantial 657% increase on Thursday [4] - Creative Global Technology Holdings Limited gained 10.7% to $4.22 after a 52% jump on Thursday [4] - Kopin Corporation increased by 8.1% to $3.20 [4] Losers - Callan JMB Inc. fell 20.7% to $3.33 after a 275% increase on Thursday due to a strategic agreement with Biostax Corp [4] - Erayak Power Solution Group Inc. decreased by 18.3% to $3.21 after an 18% rise on Thursday [4] - TryHard Holdings Limited dropped 16.4% to $6.35 following a 76% decline on Thursday due to a joint venture announcement [4] - iOThree Limited shares dipped 15% to $2.56 [4] - NOVONIX Limited fell 14% to $1.17 [4] - Moolec Science SA tumbled 13.1% to $6.69 after an 118% increase on Thursday [4] - High Roller Technologies, Inc. declined 12.9% to $20.64 after a 25% rise on Thursday [4] - Bonk, Inc. fell 10.4% to $3.55 after a 42% increase on Thursday due to acquisition news [4] - J B Hunt Transport Services Inc fell 4.2% to $197.86, reporting mixed financial results for the fourth quarter [4] - QXO Inc dipped 3.5% to $24.14 after announcing a $750 million stock offering and preliminary fourth-quarter net sales of $2.19 billion [4]

Core Viewpoint - Venus Concept Inc. is facing a challenging market outlook with a significant potential downside in its stock price, while Bone Biologics Corporation shows a more optimistic scenario among its peers [1][5][6]. Group 1: Company Performance - Venus Concept Inc. is currently trading at $2.21, with a target price of $1.64, indicating a potential downside of approximately -25.65% [1][6]. - NanoVibronix, Inc. is trading at $4.02 with a market cap of $3.20 million, but has a negative EPS of -51.81 and a PE ratio of -4.73 [2][6]. - Bone Biologics Corporation trades at $2 with a market cap of $3.61 million, showing an EPS of -2.4 and a PE ratio of -2.08 [3][6]. Group 2: Market Sentiment - Bone Biologics Corporation exhibits the highest growth potential among its peers, with a price percentage difference of 9.32%, indicating a more favorable market sentiment [4][6]. - The significant gap between the current and target price of Venus Concept Inc. suggests a pessimistic outlook from investment analysts, leading to its exclusion from coverage [1][5].

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $13.8 million, down $1.2 million, or 8% year-over-year [12] - Gross profit decreased by $1.1 million, or 11%, to $8.8 million compared to Q3 2024 [14] - Net loss attributable to stockholders for Q3 2025 was $22.6 million, or $12.14 per share, compared to a net loss of $9.3 million, or $13.10 per share for Q3 2024 [17] Business Line Data and Key Metrics Changes - Revenue from energy-based devices (EBD) increased 2% year-over-year to $9.5 million [12] - Revenue from product systems decreased by 12%, products other revenue decreased by 15%, and services revenue decreased by 5% [12] - The percentage of total systems revenue from internal lease programs was approximately 27%, up from 23% in the prior year [13] Market Data and Key Metrics Changes - U.S. revenue decreased by $1.1 million, or 12% year-over-year, while international revenue decreased by $0.2 million, or 3% year-over-year [12] - The company anticipates GLP-1 usage to grow to more than 32 million patients globally by 2030, which is expected to drive demand for its technologies [6] Company Strategy and Development Direction - The company is focusing on a turnaround strategy initiated in 2023, emphasizing the launch of the Venus Nova product as part of its strategic initiative [5][6] - The pending sale of the Venus hair business is seen as a strategic move to concentrate on the global medical aesthetics business [10] - The company aims to enhance its product portfolio to focus on total practice performance, integrating patient management from entry to post-treatment [8] Management's Comments on Operating Environment and Future Outlook - Management noted challenges in the hair restoration business due to economic uncertainty and tight credit markets affecting robotic system adoption [4] - The company is managing cash burn through disciplined cost management and is evaluating strategic alternatives to maximize shareholder value [11][19] - The company is not providing full-year 2025 financial guidance due to ongoing market conditions and strategic evaluations [19] Other Important Information - The company has made significant progress in improving its balance sheet, with cash and cash equivalents of $5.9 million and total debt obligations reduced to approximately $30.1 million [18] - The company has engaged in multiple transactions to enhance its financial profile, including a debt-to-equity exchange totaling $11.4 million [8][19] Q&A Session Summary Question: What is the outlook for the Venus hair business sale? - The company is facing challenges in closing the sale of the Venus hair business to MHG Coal Limited and is seeking assistance from the Delaware Court to meet closing conditions [9]